

BILLING & CODING GUIDE

A Resource for Coding, Billing, and Reimbursement Information for LYFGENIA™

Indication

LYFGENIA is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.

Limitations of Use

Following treatment with LYFGENIA, patients with α -thalassemia trait ($-\alpha 3.7/-\alpha 3.7$) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. LYFGENIA has not been studied in patients with more than two α -globin gene deletions.

Important Safety Information

Boxed WARNING: HEMATOLOGIC MALIGNANCY

Hematologic malignancy has occurred in patients treated with LYFGENIA. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through integration site analysis at Months 6, 12, and as warranted.

Hematologic Malignancy

Hematologic malignancy has occurred in patients treated with LYFGENIA (Study 1, Group A). At the time of initial product approval, two patients treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A) developed acute myeloid leukemia (AML). One patient with α -thalassemia trait (Study 1, Group C) has been diagnosed with myelodysplastic syndrome (MDS).

The additional hematopoietic stress associated with mobilization, conditioning, and infusion of LYFGENIA, including the need to regenerate the hematopoietic system, may increase the risk of a hematologic malignancy. Patients with sickle cell disease have an increased risk of hematologic malignancy as compared to the general population.

Patients treated with LYFGENIA may develop hematologic malignancies and should have lifelong monitoring. Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted.

In the event that a malignancy occurs, contact bluebird bio at 1-833-999-6378 for reporting and to obtain instructions on collection of samples for testing.

PLEASE NOTE:

This Billing & Coding Guide is intended to help healthcare professionals understand key billing and coding considerations for LYFGENIA and its related services when using LYFGENIA for its FDA-approved use.

The information provided in this guide is for informational and reference purposes only. The information provided in this guide should not be construed as medical or legal advice. All medical decisions should be made at the discretion of the provider. Healthcare professionals should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services rendered to individual patients. Coding and coverage policies can change, often without warning. It is the responsibility of the provider to determine coverage, reimbursement, and appropriate coding for a particular patient and/or procedure and to submit accurate claims. The information in this guide is not a guarantee of coverage or reimbursement for any product or service. Please contact your patient's health plan or work with [my bluebird support](#) for additional resources regarding coding for a specific plan.

For reimbursement questions or appeals support, talk with a Patient Navigator at [my bluebird support](#) by calling 1-833-888-6378, emailing mybluebirdsupport@bluebirdbio.com, or visiting mybluebirdsupport.com.

Please see [Important Safety Information](#) on pages 17-19 and full [Prescribing Information](#), including **Boxed WARNING**.

CPT copyright 2024 American Medical Association. All rights reserved.

Table of Contents


my bluebird support -----	<u>3</u>
<u>Treatment Journey</u> -----	<u>4</u>
<u>Access & Reimbursement Considerations</u> -----	<u>5</u>
<u>Sample Letter of Medical Necessity</u> -----	<u>6</u>
<u>Diagnosis Coding</u> -----	<u>7</u>
<u>Cell Collection Coding</u> -----	<u>8</u>
<u>Conditioning Regimen Coding</u> -----	<u>9</u>
<u>Administration Coding</u> -----	<u>10-11</u>
<u>Coding Summary</u> -----	<u>12</u>
<u>Fertility Preservation</u> -----	<u>13-14</u>
<u>Sample Claims Form</u> -----	<u>15-16</u>
<u>Indication and Important Safety Information</u> -----	<u>17-19</u>
<u>References</u> -----	<u>20</u>



We're committed to supporting your patients

my bluebird support is here to help your patients and their caregivers navigate access to bluebird bio gene therapies with resources designed to support their unique treatment paths. Examples of support range from helping to identify Qualified Treatment Center options for consultation to understanding their insurance benefits and the process for prior authorization.

With **my bluebird support**, your patient or their loved ones have a dedicated copilot to help at any point in the treatment journey. Their Patient Navigator will be available to help navigate, educate, and elevate their experience.



Navigate

Guiding your patient and their loved ones through the treatment journey while connecting them with helpful people and organizations



Educate


Sharing important resources about gene therapy and the benefits information your patient needs to access treatment with insurance



Elevate


Collaborating with your patient to help reach personal health goals

6 Important Steps to Treatment With LYFGENIA



STEP 1: Pre-Treatment

Pre-treatment involves coordinating with an individual's care team and confirming that autologous HSC transplantation is a good fit for the patient prior to mobilization and apheresis. Patients are prepared for mobilization with at least 2 cycles of scheduled transfusions (1 each month), with erythrocytapheresis being preferred.



STEP 2: Stem Cell Collection

(~7+ days)¹


Patients are required to undergo HSC mobilization* followed by apheresis to obtain CD34+ cells for LYFGENIA manufacturing. One mobilization cycle typically includes 2 consecutive days, with plerixafor mobilization and subsequent apheresis occurring on each of these days. In clinical studies, most patients collected the minimum number of CD34+ cells to manufacture LYFGENIA with 1 or 2 cycles of mobilization and apheresis, but additional cycles may be required.[†]



STEP 3: Production

(70-105 days)¹

The patient's cells are sent to a manufacturing site to produce LYFGENIA. LYFGENIA is then supplied in 1 to 4 infusion bags.



STEP 4: Conditioning and Washout

(~6+ Days)¹

Full myeloablative conditioning (4 days) is followed by a washout period of at least 48 hours prior to infusion of LYFGENIA.



STEP 5: Infusion

(~30 Minutes per Bag)¹

Each infusion bag of LYFGENIA is administered via intravenous infusion over a period of less than 30 minutes per bag. LYFGENIA is supplied in 1 or more infusion bags.



STEP 6: Post-Infusion Monitoring

(21-42 days)¹

Patients should be prepared to remain hospitalized and monitored for an additional 3-6 weeks after infusion.

After treatment with LYFGENIA, patients require long-term monitoring¹

Post-Treatment: Long-Term Follow-Up

Hematologic malignancy has occurred in patients treated with LYFGENIA; therefore, patients should be monitored lifelong. Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted.

If a malignancy is detected, contact bluebird bio at 1-833-999-NEST (6378) for reporting and to obtain instructions on collection of samples for testing.

*There is a risk of sickle cell crisis during stem cell mobilization.¹

[†]After manufacture, if the minimum dose of 3.0×10^6 CD34+ cells/kg is not met, the patient may undergo additional cycles of mobilization and apheresis, separated by at least 14 days, in order to obtain more cells for additional manufacture. Multiple drug product lots may be administered to comprise the final dose.¹

Time frames are approximate and may vary per patient.

For reimbursement questions or appeals support, talk with a Patient Navigator at [my bluebird support](#) by calling 1-833-888-6378, emailing mybluebirdsupport@bluebirdbio.com, or visiting mybluebirdsupport.com.

Please see [Important Safety Information](#) on pages 17-19 and full [Prescribing Information](#), including **Boxed WARNING**. CPT copyright 2024 American Medical Association. All rights reserved.

Access & Reimbursement Considerations

PLANNED READMISSION

If the initial cell collection is conducted during an inpatient hospital admission and patient is discharged prior to subsequent admission for administration of LYFGENIA, it may be necessary to confirm with each payer that the subsequent admission is a planned admission for gene therapy administration.

LYFGENIA

Payers may establish prior authorizations based on clinical trial inclusion and exclusion criteria, which may require documentation or physician attestation for specific diagnostic testing and clinical history.

PRIOR AUTHORIZATION CONSIDERATIONS

Testing results will be required as part of the prior authorization request. Payers may require tests such as infectious disease (e.g., HIV-1/2, hepatitis B core antibody, hepatitis B surface antigen, hepatitis C virus antibody, HTLV-1/2) and genetic testing information (e.g., beta-globin (HBB) sequencing to confirm diagnosis, alpha-globin mutation panel to rule out 2 or more deletions).

In addition, before collection of cells for manufacturing, screening for infectious diseases, specifically HIV-1/2 in accordance with clinical guidelines will be required. Payers may vary on the required testing, imaging, and biopsies for authorization; healthcare professionals should confirm with each payer prior to submission.

One mobilization cycle typically includes 2 consecutive days, with plerixafor mobilization and subsequent apheresis occurring on each of these days. The patient may undergo additional cycles of mobilization and apheresis, separated by at least 14 days, in order to obtain more cells for additional manufacture to meet minimum cell dose (3.0×10^6 CD34+ cells/kg). A collection of CD34+ cells of $\geq 16.5 \times 10^6$ CD34+ cells/kg is required for manufacturing and back-up, including $\geq 1.5 \times 10^6$ CD34+ cells/kg for back up. The back up collection may be needed for rescue treatment if there is: 1) compromise of hematopoietic stem cells or LYFGENIA before infusion, 2) primary engraftment failure, or 3) loss of engraftment after infusion with LYFGENIA.

Payers may require multiple prior authorizations for coverage of both LYFGENIA and all other ancillary services to be provided for treatment.

POST-INFUSION TESTING

Patients treated with LYFGENIA may develop hematologic malignancies and should have lifelong monitoring. Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted.

Sample Letter of Medical Necessity

LYFGENIA

Clicking on the image below will open the Sample Letter of Medical Necessity in a new window.

LYFGENIA™ (lovotibeglogene autotemcel) Sample Letter of Medical Necessity

To the Treating Physician:

This sample letter, provided by bluebird bio, Inc. is for informational purposes only, providing an example of language that may be required or helpful when responding to a request from a patient's health plan. Use of this information does not constitute medical or legal advice and does not guarantee reimbursement for coverage. It is not intended to be a substitute for, or an influence on, the independent clinical decision of the prescribing healthcare professional. Please note that some payers may have specific forms that must be completed in order to request prior authorization or to document medical necessity. When sending this information to a third-party payer for review, ensure that you submit under your practice/individual physician letterhead.

The following pages are a sample that may be customized to use as a statement of medical necessity/appeal for your patients. Use of this sample letter is not required.

Indication

LYFGENIA is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.

Limitations of Use

Following treatment with LYFGENIA, patients with α -thalassemia trait ($-\alpha 3.7/-\alpha 3.7$) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. LYFGENIA has not been studied in patients with more than two α -globin gene deletions.

Important Safety Information

Boxed WARNING: HEMATOLOGIC MALIGNANCY

Hematologic malignancy has occurred in patients treated with LYFGENIA. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through integration site analysis at Months 6, 12, and as warranted.

Hematologic Malignancy

Hematologic malignancy has occurred in patients treated with LYFGENIA (Study 1, Group A). At the time of initial product approval, two patients treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A) developed acute myeloid leukemia (AML). One patient with α -thalassemia trait (Study 1, Group C) has been diagnosed with myelodysplastic syndrome (MDS).

The additional hematopoietic stress associated with mobilization, conditioning, and infusion of LYFGENIA, including the need to regenerate the hematopoietic system, may increase the risk of a hematologic malignancy. Patients with sickle cell disease have an increased risk of hematologic malignancy as compared to the general population.

Please see Important Safety Information on pages 1-3 and full [Prescribing Information](#) for LYFGENIA, including **Boxed WARNING**

1

Additional support for medical necessity may be required for new patients. Resources available through [my bluebird support](#) include a Letter of Medical Necessity sample, which can be downloaded and adapted to reflect your patient's prior treatment journey and clinical rationale for treatment with LYFGENIA.

[Table of Contents](#)

[my bluebird
support](#)

[Treatment Journey](#)

[Access &
Reimbursement
Considerations](#)

[Sample Letter of
Medical Necessity](#)

Diagnosis Coding

[Cell Collection
Coding](#)

[Conditioning
Regimen Coding](#)

[Administration
Coding](#)

[Coding Summary](#)

[Fertility
Preservation](#)

[Sample Claims
Form](#)

[Indication and
Important Safety
Information](#)

[References](#)

Diagnosis Coding

ICD-10-CM CODE	ICD-10-CM CODE DESCRIPTOR
D57.02	Hb-SS disease with splenic sequestration
D57.03	Hb-SS disease with cerebral vascular involvement
D57.1	Sickle-cell disease without crisis
D57.20	Sickle-cell/Hb-C disease without crisis
D57.212	Sickle-cell/Hb-C disease with splenic sequestration
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement
D57.40	Sickle-cell thalassemia without crisis
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement
D57.42	Sickle-cell thalassemia beta zero without crisis
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement
D57.44	Sickle-cell thalassemia beta plus without crisis
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement

Cell Collection Coding

Mobilization and Apheresis

More than one collection session may be required to acquire the minimum dose needed for transplanting. Plerixafor should be dosed and documented based on Prescribing Information.

When apheresis is conducted during a hospital inpatient admission, the following ICD-10-PCS codes may apply:

ICD-10-PCS CODE ³	DESCRIPTION
6A550ZV	Pheresis of Hematopoietic Stem Cells, Single
6A551ZV	Pheresis of Hematopoietic Stem Cells, Multiple

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

U.S. Government End Users. CPT is commercial technical data, which was developed exclusively at private expense by the American Medical Association (AMA), 330 North Wabash Avenue, Chicago, Illinois 60611. Use of CPT in connection with this product shall not be construed to grant the Federal Government a direct license to use CPT based on FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items).

Although commonly applied for hospital outpatient mobilization and apheresis, the following CPT procedure codes may also be applicable for inpatient processes as well, based on payer-specific requirements:

CPT CODE ⁴	DESCRIPTION
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
38206*	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous

*Each code may be recorded only once per day, regardless of the quantity of bone marrow/stem cells manipulated.

HCPCS CODE ⁵	DESCRIPTION
J2562	Injection, plerixafor, 1 mg

Revenue codes are provided for informational purposes only and may vary by hospital:

REVENUE CODE ^{6,10}	DESCRIPTION
0250	Pharmacy
0636	Drugs requiring detailed coding
0871	Cell/Gene Therapy Cell Collection

Payers may vary on the required coding to appropriately reflect mobilization and apheresis for the collection of cells. Providers should confirm with each payer prior to submitting claims. If collecting cells on behalf of another institution, please confirm coding requirements with that institution as it may differ.

Conditioning Regimen Coding

Busulfan was used for conditioning in clinical trials prior to administration of LYFGENIA.¹

Due to high gonadotoxicity associated with conditioning agents, refer to the [Fertility Preservation](#) section of this guide.

ICD-10-PCS CODE ³	DESCRIPTION
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach

CPT CODE ⁴	DESCRIPTION
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour

HCPCS CODE ⁵	DESCRIPTION
J0594	Injection, busulfan, 1 mg

REVENUE CODE ⁶	DESCRIPTION
0250	General Pharmacy
0251	General Pharmacy
0260	General IV Therapy
0636	Drug Requiring Detailed Coding

10-digit NDC ⁷	DESCRIPTION
Varies	Several manufacturers produce busulfan. Therefore, providers should reference and apply the appropriate NDC code, if required by payers.

Payers may vary on their requirements for detailed coding on the delivery of any conditioning regimen associated with subsequent LYFGENIA administration. These requirements can vary based on the setting of care as well as for the patient’s specific plan. Providers should confirm requirements with individual payers.

Administration Coding

Effective July 1, 2024, LYFGENIA has been granted pass-through status and a product-specific HCPCS code (J-code) J3394 (Injection, lovotibeglogene autotemcel, per treatment).

HCPCS CODES ⁵	DESCRIPTION
J3394	Injection, lovotibeglogene autotemcel, per treatment
J3490	Unclassified drugs
J3590	Unclassified biologics
C9399	Unclassified drugs or biologicals

ICD-10-PCS codes are applied to define specific procedures during a hospital inpatient admission.

ICD-10-PCS CODES ³	DESCRIPTION
XW133H9	Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW143H9	Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9

Effective October 1, 2024, LYFGENIA has been granted a Medicare New Technology Add-on Payment (NTAP), which will remain in effect for a minimum of two years, with a potential maximum of three years. The appropriate diagnosis code and ICD-10-PCS codes (XW133H9 and XW143H9) will be used to identify inpatient LYFGENIA cases at IPPS hospitals which may be eligible for an NTAP.¹³

MS-DRG alignment—Medicare only. Applying the appropriate ICD-10-PCS code and ICD-10-CM diagnosis codes will align inpatient admissions to MS-DRG 016 or 017 for payment. It is the provider's responsibility to contact each payer for payer-specific coding requirements before submitting any claims.

MS-DRG ¹²	DESCRIPTION
016	Autologous bone marrow transplant with cc/mcc
017	Autologous bone marrow transplant without cc/mcc

CPT CODE ⁴	DESCRIPTION
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour

Administration Coding (cont'd)

REVENUE CODES ^{6,10}	DESCRIPTION
0872	Cell/Gene Therapy Specialized Biologic Processing and Storage—Prior to Transport
0873	Cell/Gene Therapy Storage and Processing after Receipt of Cells from Manufacturer
0874	Cell/Gene Therapy Infusion of Modified Cells
0892	Special Processed Drugs—FDA Approved Gene Therapy—Charges for Modified Gene Therapy

Many payers require that the LYFGENIA NDC code be reported on the claim using an 11-digit format (5-4-2) to comply with the electronic claims transaction provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).⁸

10-DIGIT NDC ⁷	11-DIGIT NDC ⁸	CLAIM REPORTING REQUIREMENTS ⁹
73554-1111-1	73554-1111-01	N473554111101UN

Payers may vary on their requirements for detailed coding on the delivery of any conditioning regimen associated with subsequent LYFGENIA administration. These requirements can vary based on the setting of care as well as for the patient’s specific plan. Providers should confirm requirements with individual payers.

One-Page Coding Summary

HOSPITAL REVENUE CODES

One or more of the following revenue codes may apply to services associated with LYFGENIA. Each payer's acceptance of and associated claim documentation for these codes should be verified.

REVENUE CODES ⁶	DESCRIPTION
0871	Cell/Gene Therapy Cell Collection
0872	Cell/Gene Therapy Specialized Biologic Processing and Storage—Prior to Transport
0873	Cell/Gene Therapy Storage and Processing after Receipt of Cells from Manufacturer
0874	Cell/Gene Therapy Infusion of Modified Cells
0892	Special Processed Drugs—FDA Approved Gene Therapy—Charges for Modified gene therapy

NDC INFORMATION

Payers may require that either a 10-digit or 11-digit format NDC code be documented on claims for LYFGENIA. The table below outlines the format options, including potential requirement of an NDC qualifier (N4).

10-DIGIT NDC ⁷	11-DIGIT NDC ⁸	DESCRIPTION
73554-1111-1	73554-1111-01	N473554 111101UN

VALUE CODE

Select payers may require a Value Code to document the invoice price for LYFGENIA.

VALUE CODE ¹⁰	DESCRIPTION
87	Invoice/acquisition cost of modified biologics. For use with Revenue Category 0892

CPT® CODES

Currently, there is no gene therapy-specific infusion code. Therefore, the following CPT® codes may be applicable for LYFGENIA administration.

CPT® CODE ⁴	DESCRIPTION
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

HCPCS LEVEL II PRODUCT CODES

Effective July 1, 2024, LYFGENIA has been granted pass-through status and a product-specific HCPCS code (J-code).

HCPCS CODES ⁵	DESCRIPTION
J3394	Injection, lovotibeglogene autotemcel, per treatment
J3490	Unclassified drugs
J3590	Unclassified biologics
C9399*	Unclassified drugs or biologicals

ICD-10-PCS INPATIENT PROCEDURE CODES

ICD-10-PCS CODES ³	DESCRIPTION
XW133H9	Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9
XW143H9	Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9

Effective October 1, 2024, LYFGENIA has been granted a Medicare New Technology Add-on Payment (NTAP). The appropriate diagnosis code and ICD-10-PCS codes (XW133H9 and XW143H9) will be used to identify inpatient LYFGENIA cases at IPPS hospitals which may be eligible for an NTAP.¹³

In all cases, providers should verify claims coding requirements by payer.

For reimbursement questions or appeals support, talk with a Patient Navigator at [my bluebird support](#) by calling 1-833-888-6378, emailing mybluebirdsupport@bluebirdbio.com, or visiting mybluebirdsupport.com.

Please see [Important Safety Information](#) on pages 17-19 and full [Prescribing Information](#), including **Boxed WARNING**. CPT copyright 2024 American Medical Association. All rights reserved.

Fertility Preservation

The myeloablative conditioning regimen associated with LYFGENIA treatment can increase risk of infertility. Therefore, consideration may be appropriate for pursuing fertility preservation.

The American Society of Clinical Oncology (ASCO)¹⁰ and the National Comprehensive Cancer Network (NCCN)¹¹ have guidance on the need for fertility preservation in patients receiving gonadotoxic therapy. This guidance may provide support in discussions with payers when pursuing coverage of preservation services. These guidelines may be found at the following links:

These links will take you to sites that are outside the control of bluebird bio, Inc. Links are provided for informational purposes only. We do not make or imply any endorsement of external websites.

<https://ascopubs.org/doi/full/10.1200/JCO.2018.78.1914>

<https://nccn.org>

Fertility preservation for iatrogenic infertility may be covered by payers. Providers should confirm covered benefits and can reference the pending treatment with myeloblastic conditioning agent(s) as a conditioning regimen for subsequent LYFGENIA treatment.

Covered services may include the following procedures when provided by or under the care or supervision of a physician:

- Collection of sperm
- Cryo-preservation of sperm
- Ovarian stimulation, retrieval of eggs and fertilization
- Oocyte cryo-preservation
- Embryo cryo-preservation

Fertility Preservation (cont'd)

CPT CODE ⁴	CPT CODE DESCRIPTOR
58321	Artificial insemination; intra-cervical
58970	Follicle puncture for oocyte retrieval, any method
89250	Culture of oocyte(s)/embryo(s), less than 4 days
89251	Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos
89253	Assisted embryo hatching, microtechniques (any method)
89254	Oocyte identification from follicular fluid
89258	Cryopreservation; embryo(s)
89259	Cryopreservation; sperm
89260	Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis
89261	Sperm isolation; complex prep (eg, Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis
89264	Sperm identification from testis tissue, fresh or cryopreserved
89268	Insemination of oocytes
89272	Extended culture of oocyte(s)/embryo(s), 4-7 days
89280	Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes
89281	Assisted oocyte fertilization, microtechnique; greater than 10 oocytes
89320	Semen analysis; volume, count, motility, and differential
89337	Cryopreservation, mature oocyte(s)
89342	Storage (per year); embryo(s)
89343	Storage (per year); sperm/semen
89346	Storage (per year); oocyte(s)

Payers may vary on their requirements for detailed coding on the delivery of any fertility preservation regimen associated with subsequent LYFGENIA administration. These requirements can vary based on the setting of care as well as for the patient's specific plan. Providers should confirm requirements with individual payers.

Sample CMS 1450 (UB-04) Claim Form for Inpatient Hospital Admissions

Clicking the image below will link to the Sample Claims Form on page 21 of this document.

Sample CMS 1450 (UB-04) Claim Form for Inpatient Hospital Admissions																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
1 PATIENT NAME										2 PATIENT ADDRESS										3a PAT. CNTRL. #										4 TYPE OF BILL																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
																				b. MED. REC. #										011X																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
																				5 FED. TAX NO.										6 STATEMENT COVERS PERIOD FROM THROUGH																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
8 PATIENT NAME										9 PATIENT ADDRESS																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																							
b										c										d										e																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			
10 BIRTHDATE										11 SEX										12 DATE										13 ADMISSION										14 TYPE										15 SRC										16 DHR										17 STAT										18										19										20										21										22										23										24										25										26										27										28										29 ACOT										30																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									
31 OCCURRENCE DATE										32 OCCURRENCE DATE										33 OCCURRENCE DATE										34 OCCURRENCE DATE										35 OCCURRENCE DATE										36 OCCURRENCE DATE										37 OCCURRENCE DATE										38										39										40										41										42										43										44										45										46										47										48										49																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																													
a										b										c										d										e										f										g										h										i										j										k										l										m										n										o										p										q										r										s										t										u										v										w										x										y										z										aa										ab										ac										ad										ae										af										ag										ah										ai										aj										ak										al										am										an										ao										ap										aq										ar										as										at										au										av										aw										ax										ay										az										ba										bb										bc										bd										be										bf										bg										bh										bi										bj										bk										bl										bm										bn										bo										bp										bq										br										bs										bt										bu										bv										bw										bx										by										bz										ca										cb										cc										cd										ce										cf										cg										ch										ci										cj										ck										cl										cm										cn										co										cp										cq										cr										cs										ct										cu										cv										cw										cx										cy										cz										da										db										dc										dd										de										df										dg										dh										di										dj										dk										dl										dm										dn										do										dp										dq										dr										ds										dt										du										dv										dw										dx										dy										dz										ea										eb										ec										ed										ee										ef										eg										eh										ei										ej										ek										el										em										en										eo										ep										eq										er										es										et										eu										ev										ew										ex										ey										ez										fa										fb										fc										fd										fe										ff										fg										fh										fi										fj										fk										fl										fm										fn										fo										fp										fq										fr										fs										ft										fu										fv										fw										fx										fy										fz										ga										gb										gc										gd										ge										gf										gg										gh										gi										gj										gk										gl										gm										gn										go										gp										gq										gr										gs										gt										gu										gv										gw										gx										gy										gz										ha										hb										hc										hd										he										hf										hg										hi										hj										hk										hl										hm										hn										ho										hp										hq										hr										hs										ht										hu										hv										hw										hx										hy										hz										ia										ib										ic										id										ie										if										ig										ih										ii										ij										ik										il										im										in										io										ip										iq										ir										is										it										iu										iv										iw										ix										iy										iz										ja										jb										jc										jd										je										jf										jg										jh										ji										jj										jk										jl										jm										jn										jo										jp										jq										jr										js										jt										ju										jv										jw										jx										jy										jz										ka										kb										kc										kd										ke										kf										kg										kh										ki										kj										kk										kl										km										kn										ko										kp										kq										kr										ks										kt										ku										kv										kw										kx										ky										kz										la										lb										lc										ld										le										lf										lg										lh										li										lj										lk										ll										lm										ln										lo										lp										lq										lr										ls										lt										lu										lv										lw										lx										ly										lz										ma										mb										mc										md										me										mf										mg										mh										mi										mj										mk										ml										mm										mn										mo										mp										mq										mr										ms										mt										mu										mv										mw										mx										my										mz										na										nb										nc										nd										ne										nf										ng										nh										ni										nj										nk										nl										nm										nn										no										np										nq										nr										ns										nt										nu										nv										nw										nx										ny										nz										oa										ob										oc										od										oe										of										og										oh										oi										oj										ok										ol										om										on										oo										op										oq										or										os										ot										ou										ov										ow										ox										oy										oz										pa										pb										pc										pd										pe										pf										pg										ph										pi										pj										pk										pl										pm										pn										po										pp										pq										pr										ps										pt										pu										pv										pw										px										py										pz										qa										qb										qc										qd										qe										qf										qg										qh										qi										qj										qk										ql										qm										qn										qo										qp										qq										qr										qs										qt										qu										qv										qw										qx										qy										qz										ra										rb										rc										rd										re										rf										rg										rh										ri										rj										rk										rl										rm										rn										ro										rp										rq										rr										rs										rt										ru										rv										rw										rx										ry										rz										sa										sb										sc										sd										se										sf										sg										sh										si										sj										sk										sl										sm										sn										so										sp										sq										sr										ss										st										su										sv										sw										sx										sy										sz										ta										tb										tc										td										te										tf										tg										th										ti										tj										tk										tl										tm										tn										to										tp										tq										tr										ts										tt										tu										tv										tw										tx										ty										tz										ua										ub										uc										ud										ue										uf										ug										uh										ui										uj										uk										ul										um										un										uo										up										uq										ur										us										ut										uu										uv										uw										ux										uy										uz										va										vb										vc										vd										ve										vf										vg										vh										vi										vj										vk										vl										vm										vn										vo										vp										vq										vr										vs										vt										vu										vv										vw										vx										vy										vz										wa										wb										wc										wd										we										wf										wg										wh										wi										wj										wk										wl										wm										wn										wo										wp										wq										wr										ws										wt										wu										wv										ww										wx										wy										wz										xa										xb										xc										xd										xe										xf										xg										xh										xi										xj										xk										xl										xm										xn										xo										xp										xq										xr										xs										xt										xu										xv										xw										xx										xy										xz										ya										yb										yc										yd										ye										yf										yg										yh										yi										yj										yk										yl										ym										yn										yo										yp										yq										yr										ys										yt										yu										yv										yw										yx										yy										yz										za										zb										zc										zd										ze										zf										zg										zh										zi										zj										zk										zl										zm										zn										zo										zp										zq										zr										zs										zt										zu										zv										zw										zx										zy										zz									

4 TYPE OF BILL¹¹

Enter the appropriate type of bill code. For example, 011X for an inpatient hospital facility.

39-41 VALUE CODES¹⁰

Payers may require a Value Code to document acquisition cost for LYFGENIA. Enter the appropriate value code(s). For example, Value Code 87 is defined as: Invoice/acquisition cost of modified biologics. For use with Revenue Category 0892

42 REVENUE CODE^{6,10}

Enter the appropriate revenue code for each reported line. For example, 0892 Charges for Gene Therapy.

43 DESCRIPTION

Enter the 11-digit NDC⁸ with an appended N4 qualifier (electronic equivalent Loop 2410, LIN02). Enter the appropriate description for corresponding revenue codes.^{6,10}

44 HCPCS⁵

Enter the HCPCS Level II code, J3394 Injection, lovotibeglogene autotemcel, per treatment, along with the applicable modifier. In lieu of a gene therapy-specific code for the infusion, the 96413 CPT⁴ code may be required.

45 SERVICE DATE

Enter the corresponding date(s) of service.

46 SERVICE UNITS

Enter appropriate units of service. For J3394, 1 unit of service is required per treatment.

47 TOTAL CHARGES

Enter total charges for each reported line.

Sample forms are for informational purposes only. The accurate completion of a claim is the responsibility of the healthcare provider. There is no guarantee regarding reimbursement for any service or item. Since requirements may vary, providers should refer to specific payer policy.

Sample CMS 1450 (UB-04) Claim Form for Inpatient Hospital Admissions (cont'd)

Clicking the image below will link to the Sample Claims Form on page 21 of this document.

PAGE		OF		CREATION DATE		TOTALS	
50 PAYER NAME		51 HEALTH PLAN ID		52 REL INFO		53 ASG BEN	
54 PRIOR PAYMENTS		55 EST. AMOUNT DUE		56 NPI		57 OTHER	
58 INSURED'S NAME		59 P REL		60 INSURED'S UNIQUE ID		61 GROUP NAME	
62 INSURANCE GROUP NO.		63 TREATMENT AUTHORIZATION CODES		64 DOCUMENT CONTROL NUMBER		65 EMPLOYER NAME	
66-69		70 PATIENT REASON DX		71 PPS CODE		72 ECI	
73		74		75		76 ATTENDING	
77		78		79		80	
81		82		83		84	
85		86		87		88	
89		90		91		92	
93		94		95		96	
97		98		99		100	
101		102		103		104	
105		106		107		108	
109		110		111		112	
113		114		115		116	
117		118		119		120	
121		122		123		124	
125		126		127		128	
129		130		131		132	
133		134		135		136	
137		138		139		140	
141		142		143		144	
145		146		147		148	
149		150		151		152	
153		154		155		156	
157		158		159		160	
161		162		163		164	
165		166		167		168	
169		170		171		172	
173		174		175		176	
177		178		179		180	
181		182		183		184	
185		186		187		188	
189		190		191		192	
193		194		195		196	
197		198		199		200	
201		202		203		204	
205		206		207		208	
209		210		211		212	
213		214		215		216	
217		218		219		220	
221		222		223		224	
225		226		227		228	
229		230		231		232	
233		234		235		236	
237		238		239		240	
241		242		243		244	
245		246		247		248	
249		250		251		252	
253		254		255		256	
257		258		259		260	
261		262		263		264	
265		266		267		268	
269		270		271		272	
273		274		275		276	
277		278		279		280	
281		282		283		284	
285		286		287		288	
289		290		291		292	
293		294		295		296	
297		298		299		300	
301		302		303		304	
305		306		307		308	
309		310		311		312	
313		314		315		316	
317		318		319		320	
321		322		323		324	
325		326		327		328	
329		330		331		332	
333		334		335		336	
337		338		339		340	
341		342		343		344	
345		346		347		348	
349		350		351		352	
353		354		355		356	
357		358		359		360	
361		362		363		364	
365		366		367		368	
369		370		371		372	
373		374		375		376	
377		378		379		380	
381		382		383		384	
385		386		387		388	
389		390		391		392	
393		394		395		396	
397		398		399		400	
401		402		403		404	
405		406		407		408	
409		410		411		412	
413		414		415		416	
417		418		419		420	
421		422		423		424	
425		426		427		428	
429		430		431		432	
433		434		435		436	
437		438		439		440	
441		442		443		444	
445		446		447		448	
449		450		451		452	
453		454		455		456	
457		458		459		460	
461		462		463		464	
465		466		467		468	
469		470		471		472	
473		474		475		476	
477		478		479		480	
481		482		483		484	
485		486		487		488	
489		490		491		492	
493		494		495		496	
497		498		499		500	
501		502		503		504	
505		506		507		508	
509		510		511		512	
513		514		515		516	
517		518		519		520	
521		522		523		524	
525		526		527		528	
529		530		531		532	
533		534		535		536	
537		538		539		540	
541		542		543		544	
545		546		547		548	
549		550		551		552	
553		554		555		556	
557		558		559		560	
561		562		563		564	
565		566		567		568	
569		570		571		572	
573		574		575		576	
577		578		579		580	
581		582		583		584	
585		586		587		588	
589		590		591		592	
593		594		595		596	
597		598		599		600	
601		602		603		604	
605		606		607		608	
609		610		611		612	
613		614		615		616	
617		618		619		620	
621		622		623		624	
625		626		627		628	
629		630		631		632	
633		634		635		636	
637		638		639		640	
641		642		643		644	
645		646		647		648	
649		650		651		652	
653		654		655		656	
657		658		659		660	
661		662		663		664	
665		666		667		668	
669		670		671		672	
673		674		675		676	
677		678		679		680	
681		682		683		684	
685		686		687		688	
689		690		691		692	
693		694		695		696	
697		698		699		700	
701		702		703		704	
705		706		707		708	
709		710		711		712	
713		714		715		716	
717		718		719		720	
721		722		723		724	
725		726		727		728	
729		730		731		732	
733		734		735		736	
737		738		739		740	
741		742		743		744	
745		746		747		748	
749		750		751		752	
753		754		755		756	
757		758		759		760	
761		762		763		764	
765		766		767		768	
769		770		771		772	
773		774		775		776	
777		778		779		780	
781		782		783		784	
785		786		787		788	
789		790		791		792	
793		794		795		796	
797		798		799		800	
801		802		803		804	
805		806		807		808	
809		810		811		812	
813		814		815		816	
817		818		819		820	
821		822		823		824	
825		826		827		828	
829		830		831		832	
833		834		835		836	
837		838		839		840	
841		842		843		844	
845		846		847		848	
849		850		851		852	
853		854		855		856	
857		858		859		860	
861		862		863		864	
865		866		867		868	
869		870		871		872	
873		874		875		876	
877		878		879		880	
881		882		883		884	
885		886		887		888	
889		890		891		892	
893		894		895		896	
897		898		899		900	
901		902		903		904	
905		906		907		908	
909		910		911		912	
913		914		915		916	
917		918		919		920	
921		922		923		924	
925		926		927		928	
929		930		931		932	
933		934		935		936	
937		938		939		940	
941		942		943		944	
945		946		947		948	
949		950		951		952	
953		954		955		956	
957		958		959		960	
961		962		963		964	
965		966		967		968	
969		970		971		972	
973		974		975		976	
977		978		979		980	
981		982		983		984	
985		986		987		988	
989		990		991		992	
993		994		995		996	
997		998		999		1000	

66-69 DIAGNOSIS CODE(S)²
Enter the appropriate ICD-10-CM diagnosis code(s). For example, D57.1 Sickle-cell disease without crisis. Field 69 is required for inpatient stay.

74 PRINCIPAL PROCEDURE³
Enter relevant ICD-10-PCS procedure code(s) with corresponding date(s) of service. For example, XW133H9: Transfusion of Lovotibeglogene Autotemcel into

Indication and Important Safety Information

Indication

LYFGENIA is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.

Limitations of Use

Following treatment with LYFGENIA, patients with α -thalassemia trait ($-\alpha 3.7/-\alpha 3.7$) may experience anemia with erythroid dysplasia that may require chronic red blood cell transfusions. LYFGENIA has not been studied in patients with more than two α -globin gene deletions.

Important Safety Information

Boxed WARNING: HEMATOLOGIC MALIGNANCY

Hematologic malignancy has occurred in patients treated with LYFGENIA. Monitor patients closely for evidence of malignancy through complete blood counts at least every 6 months and through integration site analysis at Months 6, 12, and as warranted.

Hematologic Malignancy

Hematologic malignancy has occurred in patients treated with LYFGENIA (Study 1, Group A). At the time of initial product approval, two patients treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A) developed acute myeloid leukemia (AML). One patient with α -thalassemia trait (Study 1, Group C) has been diagnosed with myelodysplastic syndrome (MDS).

The additional hematopoietic stress associated with mobilization, conditioning, and infusion of LYFGENIA, including the need to regenerate the hematopoietic system, may increase the risk of a hematologic malignancy. Patients with sickle cell disease have an increased risk of hematologic malignancy as compared to the general population.

Patients treated with LYFGENIA may develop hematologic malignancies and should have lifelong monitoring. Monitor for hematologic malignancies with a complete blood count (with differential) at least every 6 months for at least 15 years after treatment with LYFGENIA, and integration site analysis at Months 6, 12, and as warranted.

In the event that a malignancy occurs, contact bluebird bio at 1-833-999-6378 for reporting and to obtain instructions on collection of samples for testing.

Post-Marketing Long Term Follow-Up Study: Patients who intend to receive treatment with LYFGENIA are encouraged to enroll in the study, as available, to assess the long-term safety of LYFGENIA and the risk of malignancies occurring after treatment with LYFGENIA by calling bluebird bio at 1-833-999-6378. The study includes monitoring (at pre-specified intervals) for clonal expansion.

Delayed Platelet Engraftment

Delayed platelet engraftment has been observed with LYFGENIA. Bleeding risk is increased prior to platelet engraftment and may continue after engraftment in patients with prolonged thrombocytopenia. Two patients (4%) required more than 100 days post treatment with LYFGENIA to achieve platelet engraftment.

Patients should be made aware of the risk of bleeding until platelet recovery has been achieved. Monitor patients for thrombocytopenia and bleeding according to standard guidelines. Conduct frequent platelet counts until platelet engraftment and platelet recovery are achieved. Perform blood cell count determination and other appropriate testing whenever clinical symptoms suggestive of bleeding arise.

Important Safety Information (cont'd)

Neutrophil Engraftment Failure

There is a potential risk of neutrophil engraftment failure after treatment with LYFGENIA. Neutrophil engraftment failure is defined as failure to achieve three consecutive absolute neutrophil counts (ANC) $\geq 0.5 \times 10^9$ cells/L obtained on different days by Day 43 after infusion of LYFGENIA. Monitor neutrophil counts until engraftment has been achieved. If neutrophil engraftment failure occurs in a patient treated with LYFGENIA, provide rescue treatment with the back-up collection of CD34+ cells.

Insertional Oncogenesis

There is a potential risk of lentiviral vector-mediated insertional oncogenesis after treatment with LYFGENIA.

Hypersensitivity Reactions

Allergic reactions may occur with the infusion of LYFGENIA. The dimethyl sulfoxide (DMSO) or dextran 40 in LYFGENIA may cause hypersensitivity reactions, including anaphylaxis.

Anti-retroviral Use

Patients should not take prophylactic HIV anti-retroviral medications for at least one month prior to mobilization and until all cycles of apheresis are completed. There are some long-acting anti-retroviral medications that may require a longer duration of discontinuation for elimination of the medication. If a patient is taking anti-retrovirals for HIV prophylaxis, confirm a negative test for HIV before beginning mobilization and apheresis of CD34+ cells.

Hydroxyurea Use

Patients should not take hydroxyurea for at least 2 months prior to mobilization and until all cycles of apheresis are completed. If hydroxyurea is administered between mobilization and conditioning, discontinue 2 days prior to initiation of conditioning.

Iron Chelation

Drug-drug interactions between iron chelators and the mobilization process and myeloablative conditioning agent must be considered. Iron chelators should be discontinued at least 7 days prior to initiation of mobilization or conditioning. Do not administer myelosuppressive iron chelators (e.g., deferiprone) for 6 months post-treatment with LYFGENIA.

Non-myelosuppressive iron chelation should be restarted no sooner than 3 months after LYFGENIA infusion. Phlebotomy can be used in lieu of iron chelation, when appropriate.

Interference with PCR-based Testing

Patients who have received LYFGENIA are likely to test positive by polymerase chain reaction (PCR) assays for HIV due to integrated BB305 LVV proviral DNA, resulting in a possible false-positive PCR assay test result for HIV. Therefore, patients who have received LYFGENIA should not be screened for HIV infection using a PCR-based assay.

Adverse Reactions

The most common adverse reactions \geq Grade 3 (incidence $\geq 20\%$) were stomatitis, thrombocytopenia, neutropenia, febrile neutropenia, anemia, and leukopenia.

Three patients died during LYFGENIA clinical trials; one from sudden cardiac death due to underlying disease and two from acute myeloid leukemia who were treated with an earlier version of LYFGENIA using a different manufacturing process and transplant procedure (Study 1, Group A).

Important Safety Information (cont'd)

Pregnancy/Lactation

Advise patients of the risks associated with myeloablative conditioning agents, including on pregnancy and fertility.

LYFGENIA should not be administered to women who are pregnant, and pregnancy after LYFGENIA infusion should be discussed with the treating physician.

LYFGENIA is not recommended for women who are breastfeeding, and breastfeeding after LYFGENIA infusion should be discussed with the treating physician.

Females and Males of Reproductive Potential

A negative serum pregnancy test must be confirmed prior to the start of mobilization and re-confirmed prior to conditioning procedures and before LYFGENIA administration.

Women of childbearing potential and men capable of fathering a child should use an effective method of contraception (intra-uterine device or combination of hormonal and barrier contraception) from start of mobilization through at least 6 months after administration of LYFGENIA.

Advise patients of the options for fertility preservation.



(lovotibeglogene autotemcel)
suspension for IV infusion

References

1. LYFGENIA [prescribing information], Somerville, MA; bluebird bio, Inc. December 2023.
2. Centers for Disease Control and Prevention. ICD-10-CM Diagnosis Codes. National Center for Health Statistics – ICD-10-CM. Accessed September 2023 at: <https://icd10cmtool.cdc.gov/?fy=FY2024>
3. Centers for Medicare & Medicaid Services. ICD-10-PCS Codes. Accessed September 2023 at: <https://www.cms.gov/files/zip/2023-icd-10-pcs-codes-file-updated-01/11/2023.zip> Open zip file then text document: [icd10pcs_codes_2023](#)
4. *CPT® 2023 Professional Edition*. Fourth ed. Chicago, IL: American Medical Association; 2022.
5. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Release & Code Sets. HCPCS Quarterly Update. Accessed July 2024 at: <https://www.cms.gov/files/document/r12665cp.pdf>
6. Noridian Healthcare Solutions. Hospital Revenue Codes. Accessed September 2023 at: <https://med.noridianmedicare.com/web/jea/topics/claim-submission/revenue-codes>
7. US Food and Drug Administration NDC Code Directory. Accessed December 2023 at: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm
8. US Food & Drug Administration. Proposed Rule on Revising the National Drug Code Format. Accessed September 2023 at: <https://www.fda.gov/drugs/drug-approvals-and-databases/proposed-rule-revising-national-drug-code-format>
9. CIGNA Resources. Coding Guidelines for Drug-Related Medical Claims. Accessed September 2023 at: <https://static.cigna.com/assets/chcp/resourceLibrary/medicalResourcesList/medicalDoingBusinessWithCigna/codingGuidelinesForDrugRelatedMedicalClaims.html>
10. National Uniform Billing Committee (NUBC). Summary of Gene and Cell Therapy Coding Changes. Accessed September 2023 at: <https://www.nubc.org/system/files/media/file/2020/02/Cell-Gene%20Therapy%20Code%20Changes.pdf>
11. Noridian Healthcare Solutions. Type of Bill code Structure. Accessed September 2023 at: <https://med.noridianmedicare.com/web/jea/topics/claim-submission/bill-types>
12. Centers for Medicare & Medicaid Services. MS-DRG Classifications and Software. FY 2024 - Version 41. Accessed October 2023 at <https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/ms-drg-classifications-and-software>. Open Zip folder ICD-10 MS-DRG Definitions Manual Files V41, then open text document [mdcs_00_07](#).
13. Department of Health and Human Services. Centers for Medicare & Medicaid Services. CMS-1808-F Medicare Program; Medicare and Medicaid Programs and the Children's Health Insurance Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2025 Rates; Quality Programs Requirements; and Other Policy Changes. Accessed August 1 2024. <https://public-inspection.federalregister.gov/2024-17021.pdf>.

Links to external third-party websites are outside the control of bluebird bio, Inc. and are provided for informational purposes only. bluebird bio does not make or imply any endorsement of external websites.



Please see [Important Safety Information](#) on pages 17-19 and full [Prescribing Information](#), including **Boxed WARNING**.

CPT copyright 2024 American Medical Association. All rights reserved.

bluebird bio, the bluebird bio logo, LYFGENIA, the LYFGENIA logo, and the my bluebird support logo are trademarks of bluebird bio, Inc.

© 2024 bluebird bio, Inc. All rights reserved. LYF-US-00033-v3 10/24



Sample CMS 1450 (UB-04) Claim Form for Inpatient Hospital Admissions

[illegible]